Evidence map›Paper›PMID 33392444›Full record

ArticleJNCI cancer spectrum2020

Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews.

Marina T Van Leeuwen, Steven Luu, Howard Gurney, Martin R Brown, Sallie-Anne Pearson, Kate Webber, Lee Hunt, Soojung Hong, Geoffrey P Delaney, Claire M Vajdic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Navigating the Complexities of Cancer Treatment-Induced Hypertension.Journal of cardiovascular development and disease · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marina T Van LeeuwenCentre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-1570-2852
Steven LuuCentre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia.
Howard GurneyFaculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
Martin R BrownFaculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
Sallie-Anne PearsonCentre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia.
Kate WebberDepartment of Oncology, Monash Health, Clayton, Victoria, Australia.
Lee HuntCancer Voices NSW, Milsons Point, New South Wales, Australia.
Soojung HongCentre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-4350-2794
Geoffrey P DelaneyLiverpool Cancer Therapy Centre, Liverpool, New South Wales, Australia.
Claire M VajdicCentre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-3612-8298

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral targeted therapies for cancer have been associated with cardiovascular toxicity. The evidence for this association has not been synthesized systematically nor has the quality of evidence been considered. We synthesized systematic review evidence of cardiovascular toxicity of individual targeted agents.

methodsWe searched MEDLINE, Embase, and the Cochrane Database of Systematic Reviews for systematic reviews with meta-analyses of cardiovascular outcomes for individual agents published to May 2020. We selected reviews according to prespecified eligibility criteria (International Prospective Register of Systematic Reviews CRD42017080014). We classified evidence of cardiovascular toxicity as sufficient, probable, possible, or indeterminate for specific cardiovascular outcomes based on statistical significance, study quality, and size.

resultsFrom 113 systematic reviews, we found at least probable systematic review evidence of cardiovascular toxicity for 18 agents, including high- and all-grade hypertension for bevacizumab, ramucirumab, axitinib, cediranib, pazopanib, sorafenib, sunitinib, vandetanib, aflibercept, abiraterone, and enzalutamide, and all-grade hypertension for nintedanib; high- and all-grade arterial thromboembolism (includes cardiac and/or cerebral events) for bevacizumab and abiraterone, high-grade arterial thromboembolism for trastuzumab, and all-grade arterial thromboembolism for sorafenib and tamoxifen; high- and all-grade venous thromboembolism (VTE) for lenalidomide and thalidomide, high-grade VTE for cetuximab and panitumumab, and all-grade VTE for bevacizumab; high- and all-grade left ventricular ejection fraction decline or congestive heart failure for bevacizumab and trastuzumab, and all-grade left ventricular ejection fraction decline/congestive heart failure for pazopanib and sunitinib; and all-grade corrected QT interval prolongation for vandetanib.

conclusionsOur review provides an accessible summary of the cardiovascular toxicity of targeted therapy to assist clinicians and patients when managing cardiovascular health.

Identifiers

PMID33392444
PMCPMC7768929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.